AstraZeneca Inks Research Pact With China’s CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion

All NewsJune 13, 2025

AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent